ストックスクリーナーアプリを入手
7.46
2.19%
0.16
アフターアワーズ：
7.30
-0.16
-2.14%
Xbiotech Inc (XBIT) 最新ニュース
XBiotech (NASDAQ:XBIT) Share Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
(XBIT) Technical Pivots with Risk Controls - Stock Traders Daily
Desmoplastic Small Round Cell Tumor Treatment Market Overall - openPR
XBiotech (NASDAQ:XBIT) Stock Passes Above 50 Day Moving AverageShould You Sell? - MarketBeat
How the (XBIT) price action is used to our Advantage - Stock Traders Daily
Enerflex Ltd. (NYSE:EFXT) Stake Increased by The Manufacturers Life Insurance Company - Defense World
Alopecia Areata Market Analysis, Size, Market Report 2024-2033 - WhaTech
76,460 Shares in XBiotech Inc. (NASDAQ:XBIT) Acquired by American Century Companies Inc. - Defense World
American Century Companies Inc. Acquires Shares of 76,460 XBiotech Inc. (NASDAQ:XBIT) - MarketBeat
Cancer Antigen Market Size Is Booming Worldwide with Share, Size, Top Key Players - Talented India
Rhumbline Advisers Has $103,000 Stock Holdings in XBiotech Inc. (NASDAQ:XBIT) - Defense World
Rhumbline Advisers Has $335,000 Stock Position in The First of Long Island Co. (NASDAQ:FLIC) - Defense World
Bank of New York Mellon Corp Buys 49,863 Shares of XBiotech Inc. (NASDAQ:XBIT) - Defense World
XBiotech (NASDAQ:XBIT) vs. Harmony Biosciences (NASDAQ:HRMY) Financial Contrast - Defense World
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.63 - Defense World
XBiotech (NASDAQ:XBIT) Stock Price Passes Above 50-Day Moving Average of $6.63 - MarketBeat
Objective long/short (XBIT) Report - Stock Traders Daily
XBiotech (NASDAQ:XBIT) Shares Pass Above 50-Day Moving Average of $6.47 - MarketBeat
XBiotech (NASDAQ:XBIT) Stock Crosses Above Fifty Day Moving Average of $6.47 - Defense World
Is XBiotech (NASDAQ:XBIT) Weighed On By Its Debt Load? - Simply Wall St
Hidradenitis Suppurativa Market Demand, Share, Size, Trends, Forecast To 2033 - WhaTech
Cancer Cachexia Market Forecasted to Reach $3.14 Billion by 2028 with a CAGR of 6.2% - GlobeNewswire Inc.
XBiotech Inc. (NASDAQ:XBIT) Stock Holdings Increased by Vanguard Group Inc. - Defense World
XBiotech (NASDAQ:XBIT) Stock Crosses Above Fifty Day Moving Average of $6.22 - MarketBeat
XBiotech (NASDAQ:XBIT) Shares Pass Above 50 Day Moving Average of $6.22 - Defense World
XBiotech: Q2 Earnings Snapshot - CT Insider
XBIT Stock Earnings: XBiotech Reported Results for Q2 2024 - InvestorPlace
(XBIT) Trading Signals - Stock Traders Daily
XBiotech (NASDAQ:XBIT) Stock Crosses Above 50 Day Moving Average of $6.35 - Defense World
XBiotech Inc. (NASDAQ:XBIT) most popular amongst retail investors who own 51%, insiders hold 35% - Yahoo Finance
XBiotech (NASDAQ:XBIT) Stock Crosses Above 50-Day Moving Average of $6.35 - MarketBeat
(XBIT) Investment Analysis - Stock Traders Daily
XBiotech Inc. (NASDAQ:XBIT) Sees Significant Increase in Short Interest - MarketBeat
XBiotech Inc. (NASDAQ:XBIT) Shares Acquired by Empowered Funds LLC - Defense World
XBiotech Inc. (NASDAQ:XBIT) Sees Large Decrease in Short Interest - Defense World
XBiotech Inc. (NASDAQ:XBIT) Short Interest Update - MarketBeat
Pancreatic Cancer Market to Grow Rapidly by 2034, Predicts DelveInsight | Key CompaniesFibroGen, OSE Immunotherapeutics, Panbela Therapeutics, Lokon Pharma, Helix Biopharma, Tvardi Therapeutics, BioNTech, XBiotech, Lumicell, CARsgen Ther - Yahoo Finance
Long Term Trading Analysis for (XBIT) - Stock Traders Daily
XBiotech Inc. (NASDAQ:XBIT) surges 26%; individual investors who own 51% shares profited along with insiders - Simply Wall St
XBiotech (NASDAQ:XBIT) Shares Pass Below 50-Day Moving Average of $7.29 - MarketBeat
XBiotech (NASDAQ:XBIT) Share Price Crosses Below 50 Day Moving Average of $7.29 - Defense World
XBiotech Inc (XBIT) Stock: Navigating a Year of Volatility - The InvestChronicle
Analyzing Ratios: XBiotech Inc (XBIT)'s Financial Story Unveiled – DWinneX - The Dwinnex
Vertus Energy raises €8.75M Seed for Waste-to-X biotech solutions - Tech.eu
What Kind Of Investor Owns Most Of XBiotech Inc. (NASDAQ:XBIT)? - Yahoo New Zealand News
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? - MSN
The Psychology of XBiotech Inc Inc. (XBIT) Price Performance: Understanding Market Sentiment - The InvestChronicle
Les résultats de XBiotech d’une étude randomisée de phase 1/2 en double aveugle suggèrent l’émergence d’un traitement révolutionnaire potentiel contre le cancer du pancréas avancé - GlobeNewswire Inc.
What's Going On With Small-Cap Cancer Focused XBiotech On Tuesday? By Benzinga - Investing.com UK
XBiotech Studies Find Potential Treatment for Advanced Pancreatic Cancer - MarketWatch
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for ... - Markets Insider
XBITXBiotech Inc. Latest Stock News & Market Updates - StockTitan
XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer - Yahoo Finance
2.02%
0.47%
大文字化:
|
ボリューム (24 時間):